

States Look Inward as Health Tabs Loom Large

BY ALICIA AULT
Associate Editor, Practice Trends

WASHINGTON — With health care costs accounting for the single largest expense in their budgets, states are increasingly looking for solutions from within, not from the federal government, according to an annual accounting of state legislative trends compiled by the Blue Cross and Blue Shield Association.

“Health care spending represented nearly one-third of total state expenditures last fiscal year,” said Susan Laudicina, BCBSA director for state research and policy at a briefing for reporters. And, she noted, as the economy weakens, health care costs will continue to rise, while tax revenues will fall. That will add to the pressure to find creative solutions, she said.

“The challenge for state lawmakers is how to avoid cutting existing programs like Medicaid and the State Children’s Health Insurance Program while also finding new ways to cover the uninsured and contain costs,” said Ms. Laudicina.

The most significant trend observed in the states: an attempt to expand coverage. About half of the state legislatures debated universal coverage or expansion programs for children in fiscal 2007. State mandates requiring individuals to buy insurance were introduced in 12 states. All of those failed, largely because they are controversial, said Ms. Laudicina.

Connecticut and New York expanded eligibility for SCHIP to 400% of the federal poverty level and seven other states raised eligibility to 300%, but those efforts are threatened by a rule change issued by the Department of Health and Human Services last August that ostensibly caps eligibility at 250% of the federal poverty level. Eight states have sued to challenge that ruling.

Eight states—Connecticut, Indiana,

Kansas, Louisiana, Maryland, New York, Texas and Washington—created programs in which public funds are used to subsidize the cost of private employer-sponsored health insurance to Medicaid-eligible workers. Oklahoma expanded its existing subsidy program, making more people eligible.

So-called “transparency” initiatives are gaining ground, also. These are proposals that require hospitals—and in some cases, physicians—to publicly share information on infections and other adverse events, and

also other quality data and pricing. Twenty-one states debated proposals that would require transparency on some level. Transparency bills were enacted in 10 states: Arkansas, Delaware, Georgia, Indiana, Minnesota, New Jersey, Oregon, Pennsylvania, Texas, and Washington.

In Texas, for instance, the state is now requiring hospitals and physicians to provide patients with estimates of charges if requested. Hospitals will also be required to tell patients if there is the possibility that an


out-of-network provider will be working in an in-network facility, and to inform them there may be costs to the patient as a result. The Texas law reflects a growing concern that patients aren’t aware that they may be balance-billed, Ms. Laudicina said.

Eleven states will take up transparency measures in 2008, she said. The annual State Legislative Health Care and Insurance Issues report compiles information from the BCBSA’s survey of 39 independent Blue Cross and Blue Shield plans. ■

SKIN DISEASE EDUCATION FOUNDATION and Ob.Gyn. News present

WOMEN’S & PEDIATRIC DERMATOLOGY SEMINAR 2008™

A CONTINUING MEDICAL EDUCATION CONFERENCE
SEPTEMBER 18-21, 2008



GRAND HYATT
SAN FRANCISCO

Learn the latest techniques and therapies for diagnosing and treating a broad spectrum of dermatological disorders for women and children. An outstanding faculty will present an impressive scientific program designed to improve patient care and enhance your practice. For information about early registration savings, visit www.sdefderm.com.

FEATURING:

Women’s Sessions*

- Hair Loss in Women
- Genital Vulvar Diseases
- Melanoma and Non-Melanoma Skin Cancers
- Vitamin D - Bones and Sunscreens
- Acne and Rosacea in Women - Topical and Systemic Options
- Best Treatments for Melasma, Lentigos, and other Pigmentary Concerns
- Allergic Contact Dermatitis to Cosmetics, Lotions, and Potions
- Cutaneous Lupus and Dermatomyositis
- Update on Lasers and Fillers

Pediatric Sessions*

- Atopic Dermatitis
- Pediatric Contact Dermatitis
- Hot Topics in Pediatric Dermatology
- Acne in the Pediatric and Adolescent Patient
- Warts and Molluscum
- Using Biologics and Immunosuppressives in Childhood Psoriasis
- Surgical Procedures for Tots
- Congenital and Acquired Pigmentary Disorders
- Neonatal Dermatology

*All topics subject to change

This activity have been approved for AMA PRA Category 1 Credits™

Jointly sponsored by



SKIN DISEASE EDUCATION FOUNDATION
an Elsevier business

The opinions expressed at Skin Disease Education Foundation seminars do not necessarily reflect those of Skin Disease Education Foundation, Elsevier Inc. or the supporters of the seminars. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in presentations, including any claims related to the products, drugs or services mentioned.

SEMINAR DIRECTORS:



Sheila Fallon Friedlander, MD
Clinical Professor of Pediatrics & Medicine, Dermatology
University of California, San Diego, CA
Rady Children’s Hospital, San Diego, CA



Maria Hordinsky, MD
Professor, Head, Department of Dermatology
University of Minnesota, Minneapolis, MN

MEDICAL DIRECTOR:



Joseph F. Fowler, Jr., MD
Clinical Professor of Dermatology
University of Louisville, Louisville, KY
Dermatology Specialists PSC, Louisville, KY

COSMETIC DERMATOLOGY DIRECTORS:



David J. Goldberg, MD, JD
Clinical Professor, Mount Sinai School of Medicine
Director, Skin Laser & Surgery Specialists of NYINJ
New York, NY



Christopher B. Zachary, MBBS, FRCP
Professor and Chair, Department of Dermatology
University of California, Irvine, CA

INDEX OF ADVERTISERS

Bayer HealthCare Pharmaceuticals Inc.	
YAZ	3-4
Conceptus Incorporated	
Essure	11
Duramed Pharmaceuticals, Inc. (a subsidiary of Barr Pharmaceuticals)	
Enjuvia	5-6
Amniscreen	32
Seasonique	43-44
ETHICON, Inc.	
Thermachoice	9
GlaxoSmithKline Consumer Healthcare	
Tums	33
Hologic, Inc.	
FullTerm	17
Eli Lilly and Company	
Evista	12-16
Merck & Co., Inc.	
Gardasil	30a-30b
Sciele Pharma, Inc.	
Fosteum	7-8
Takeda Pharmaceuticals North America, Inc.	
Rozerem	28-30
Ther-Rx Corporation	
Evamist	22-25
Union-Swiss	
Bio-Oil	19
Wyeth Consumer Healthcare	
Caltrate	21

SAVE THE DATE **SEPTEMBER 18 - 21, 2008**

Visit www.sdefderm.com and take advantage of Early Registration Savings now!